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Abstract
Background: The availability of methotrexate and the introduction of multiple biological agents have revolutionized
the treatment of juvenile idiopathic arthritis (JIA). Several international and national drug registries have been
implemented to accurately monitor the long-term safety/efficacy of these agents. This report aims to present the
combined data coming from Pharmachild/PRINTO registry and the national registries from Germany (BiKeR) and Sweden.
Methods: Descriptive statistics was used for demographic, clinical data, drug exposure, adverse events (AEs) and events
of special interest (ESIs). For the Swedish register, AE data were not available.
Results: Data from a total of 15,284 patients were reported: 8274 (54%) from the Pharmachild registry and 3990 (26%)
and 3020 (20%) from the German and the Swedish registries, respectively. Pharmachild children showed a younger age
(median of 5.4 versus 7.6 years) at JIA onset and shorter disease duration at last available visit (5.3 versus 6.1–6.8) when
compared with the other registries. The most frequent JIA category was the rheumatoid factor–negative polyarthritis
(range of 24.6–29.9%). Methotrexate (61–84%) and etanercept (24%–61.8%) were the most frequently used synthetic and
biologic disease-modifying anti-rheumatic drugs (DMARDs), respectively. There was a wide variability in glucocorticoid use
(16.7–42.1%). Serious AEs were present in 572 (6.9%) patients in Pharmachild versus 297 (7.4%) in BiKeR. Infection and
infestations were the most frequent AEs (29.4–30.1%) followed by gastrointestinal disorders (11.5–19.6%). The most
frequent ESIs were infections (75.3–89%).
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Conclusions: This article is the first attempt to present a very large sample of data on JIA patients from different national
and international registries and represents the first proposal for data merging as the most powerful tool for future analysis
of safety and effectiveness of immunosuppressive therapies in JIA.
Registry registration: The Pharmachild registry is registered at ClinicalTrials.gov (NCT01399281) and at the European
Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) (http://www.encepp.eu/encepp/
viewResource.htm?id=19362). The BiKeR registry is registered at ENCePP (http://www.encepp.eu/encepp/viewResource.
htm?id=20591).
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Background
Juvenile idiopathic arthritis (JIA) [1] is the most com-
mon chronic pediatric rheumatic disease and an import-
ant cause of short- and long-term disability and
quality-of-life impairment [2–8]. Although none of the
available drugs for JIA has curative potential, prognosis
has greatly improved as the result of substantial progress
in disease management with the introduction of bio-
logics. Despite the good efficacy results of all phase III
trials on biologic agents, the long-term safety profile
needs to be further characterized. For example, spontan-
eous reporting from countries with a low incidence of
tuberculosis suggested that tuberculosis might be prob-
lematic in patients treated with biologics [9]. In August
2009, the US Food and Drug Administration (FDA) an-
nounced through a boxed warning that an increased risk
of certain cancers in children might occur, and labeling
for the tumor necrosis factor (TNF) blocker products
was updated [10–14]. A Cochrane review from February
2011 compared the adverse events (AEs) of biologics
and concluded that there is an urgent need for more re-
search regarding their long-term safety of different bio-
logics [15]. The availability of a large observational
international and national registry could enable clini-
cians and regulatory agencies to properly monitor the
long-term or rare safety events and effectiveness of these
agents in the relatively low prevalent JIA.
The aim of this project is to present the combined
data of the “Pharmacovigilance in JIA patients treated
with biologic agents and/or MTX” (Pharmachild) inter-
national registry and two consenting JIA national regis-
tries: the “Biologics in Pediatric Rheumatology Registry”
(BiKeR) from Germany and the JIA registry from
Sweden. The secondary goal was to test a sharing system
for future merging of data to address specific JIA scien-
tific and clinical questions.
Methods
Description of registries
The Pharmachild registry
Pharmachild is an observational international registry
that started in 2011 with European Union initial funding
support and that enrolled children from member centers
of the Paediatric Rheumatology International Trials Or-
ganisation (PRINTO) [16].
Inclusion criteria were children with JIA as per Inter-
national League of Associations for Rheumatology
(ILAR) criteria [17] receiving biologics or other synthetic
disease-modifying anti-rheumatic drugs (DMARDs) as
per physician decision. The registry contains two specific
populations. The first is a retrospective cohort of all pa-
tients under treatment or previously treated with
DMARDs by one-time clinical chart revision of safety
events and complete drug exposure since disease onset
to last available follow-up. The second is a prospective
cohort including all cases newly treated with DMARDs
since enrollment in the registry and cases still under
treatment with any drug. To avoid selection bias, each
center performed a census for all patients previously
treated with DMARDs at that specific center, used as
the reference to evaluate the enrollment capability. In a
second step, the center entered retrospective data, con-
sidered successful if they retrieved at least 70% of the pa-
tients listed in the census. Finally, in a third step, the
prospective data collection started.
Data collection included full and complete details for
ILAR classification criteria; demographic, clinical, and
laboratory information; and efficacy (only for the pro-
spective cohort) and safety data on a long-term basis.
Centers reported the whole drug exposure of the patient
along with dates of start and discontinuation of the drug,
dosages, route of administration, reasons for discontinu-
ation, and possible correlation with the AEs. All the AEs
of at least moderate/severe/very severe intensity and ser-
ious AEs, using the latest release of the Medical Diction-
ary for Regulatory Activities (MedDRA) dictionary, were
reported; mild intensity was reported only for those AEs
which did not resolve and require a follow-up report.
Some AEs were classified as by consensus of PRINTO
members as events of special interest (ESIs).
Efficacy data were collected in the prospective cohort
through the JIA core set measures with whole joint
count [18], the disease activity status measured through
the Juvenile Arthritis Disease Activity Score (JADAS),
Swart et al. Arthritis Research & Therapy          (2018) 20:285 Page 2 of 11
and the annual evaluation of damage through the Juven-
ile Arthritis Damage Index (JADI) [19] and of growth
and pubertal development and key information on im-
aging and bio-specimen local collection. As patient-re-
ported outcome (PRO), families completed online the
Juvenile Arthritis Multidimensional Assessment Report
(JAMAR) [20] before the scheduled clinic visit or in the
hospital (on tablets or paper) in order to provide key
notes to the treating physician before the clinical
examination.
The system also provided data on drug exposure and
occurrence of AEs (Fig. 1) as a tool to discuss the health
status of a patient with the family.
Data collection was performed online via the secured
PRINTO website on a dedicated server with a username
and timely password on an https-encrypted platform.
English was the official language used for all forms com-
pleted by the physicians, and the PROs were available in
the appropriate language spoken by parents/patients.
The web system was designed to be user-friendly, modu-
lar, and upgradable. During data entry, several hundred
automatic checks were in place to ensure data quality
and consistency. In particular, safety events were
checked for accuracy by PRINTO-certified MedDRA
coders, which could go back to the center with elec-
tronic query tickets in case of missing or unclear infor-
mation (Additional file 1). A designated pediatric
rheumatologist acted as medical monitor (JS) by per-
forming an electronic check and revision of the AEs and
ESIs; in addition, for some ESIs (for example, infection),
adjudicating committees were in place.
The BiKeR registry
The BiKeR registry in Germany focused, from 2001, on
AEs and efficacy data in patients treated with etanercept
(ETN), the first biologic licensed in Germany [21]. From
that time, surveillance was extended to all biologics ap-
proved for JIA [22–24]. Information on biologics not ap-
proved for JIA was also collected for such patients who
have been admitted for an approved biologic if patients
were switched. The BiKeR registry was founded by
pharmaceutical companies with independent bilateral
contracts. BiKeR was approved by the ethics committee
of the physician board of Aerztekammer Nordrhein,
Düsseldorf. The BiKeR registry includes about 80 study
sites and since its inception has followed more than
4000 patients in Germany and Austria who were 2 to 18
years old and who meet the ILAR criteria for JIA. Writ-
ten consent was obtained from patients and parents and
repeated if the patient became an adult. Only pseudony-
mized data were collected.
Patient demographic characteristics, disease history,
and previous treatments are documented at the time of
patient enrollment. Details about relevant treatment and
reasons for discontinuation, concomitant therapy, dis-
ease activity, and AEs are prospectively collected by
using standard case report forms (CRFs) at the start of
treatment, at months 3 and 6, and every 6 months there-
after. Safety was analyzed on the basis of AE reporting.
All reported AEs defined as any untoward medical oc-
currence in a subject administered a pharmaceutical
product, even without a causal relationship with the
treatment, were analyzed. Serious AEs and ESIs were de-
fined as in Pharmachild. Onsite monitoring is performed
in selected larger centers covering about 80% of admit-
ted patients. In 2005, the registry was extended to in-
clude a control group of 1500 biologic-naïve JIA patients
who started with the synthetic DMARD such as MTX to
enable comparison of patients exposed to biologics with
unexposed JIA cohorts [25, 26]. The “Juvenile arthritis
MTX/Biologics long-term Observation” (JUMBO) was
launched in 2007 to include data on long-term safety
after transition to adulthood [27]. At present, 3990 pa-
tients are included in the JUMBO registry.
The Swedish registry
In 2009, the Swedish JIA registry began to follow all
children on biologics and later expanded to all patients
treated with or without DMARDs. Reports from care
givers, patients, and medical records using JADAS,
quality-of-life questionnaires, and arthritis-specific ques-
tions were included in the registry, which after 5 years
includes 1700 children (60% of the total JIA population
and above 90% of patients on cytokine modulators). Data
on treatment as well as disease course and efficacy were
included, while data on safety were not available [28].
Statistics
All registries and participating centers obtained approval
from their respective ethics committee and obtained
consent/assent based on existing national regulations.
Pharmachild, BiKeR, and the Swedish registries re-
ported cumulative summary data into predefined spread-
sheets in order to provide baseline descriptive statistics
of demographic and clinical data. Safety data were avail-
able only for Pharmachild and BiKeR. ESIs common to
the two registries are reported.
For qualitative data, frequencies (percentage) were re-
ported, while quantitative data were expressed in terms
of medians with first and third quartiles. No formal stat-
istical comparisons were performed.
Results
Demographic characteristics and drug exposure
In Pharmachild, 11,796 patients in total were registered
in the census registry as of January 2017 from 98
PRINTO centers in 32 countries. Clinical and safety data
were provided for 8274 (70.1%) out of 11,796 patients
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belonging to 86 participating centers. Sixty out (61.2%)
of eighty-six centers provided at least 70% safety data of
their local JIA patients, and the median was 55 patients
per center. Prospective data were collected for a total of
3070 patients.
Table 1 reports the demographic and clinical data for a
total of 15,284 patients: 8274 (54.1%) from the Pharma-
child registry and 3990 (26.1%) from the German BiKeR
and 3020 (19.8%) from the Swedish registry. The pa-
tients included in the German and Swedish registries
were not overlapping with those in Pharmachild since
the registries were created in different periods and in-
cluded data from different patients with the same
disease.
Patients coming from the Pharmachild database
showed a younger age (median of 5.4 years versus
Fig. 1 Pharmachild graphical depiction over time of the key efficacy and safety data. Drug exposure and adverse events are represented in
parallel to Juvenile Arthritis Disease Activity Score (JADAS) pattern. The Excel spreadsheet with all the data could be downloaded automatically by
all participating centers. In the figure, an example of a patient from an Italian center is presented
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7.6) at onset and shorter disease duration (5.3 versus
6.1–6.8) at the last available follow-up visit in com-
parison with the other registries. BiKeR reported a
lower median number of children per center (10.5
versus 52–55.5). Antinuclear antibody (ANA) positiv-
ity was higher in BiKeR and missing in the Swedish
registry.
The JIA category distribution differed among regis-
tries, but the most frequent JIA category was rheumatoid
factor (RF)–negative polyarthritis (range of 24.6%–
29.9%). The frequency of oligoarticular JIA was higher in
the Swedish registry (49.6% versus about 30.5%–37.1% in
the other two registries), while in BiKeR the frequencies
of oligo- and poly-articular JIA RF-negative were similar
(about 30%); Pharmachild depicted a higher frequency of
systemic JIA (11% versus 4.7–6.7% in the German and
Swedish registries, respectively).
Table 2 reports the number of patients who ever re-
ceived a drug from onset to last available follow-up visit,
with the corresponding days of drug exposure per medi-
cation from the first day of drug administration to the
last available follow-up visit, excluding the days off ther-
apy for any reason.
There was a global trend to use MTX as a
first-choice synthetic DMARD and ETN as a first-line
biologic, but the Swedish registry used these drugs in
a lower percentage of patients (MTX 61% versus
about 84% in Pharmachild and BiKeR; ETN 24% ver-
sus 43.5% in Pharmachild and 61.8% in BiKeR). Des-
pite the similar percentage of patients using these
medications, children from BiKeR were exposed for a
shorter period to the drugs compared with Pharma-
child children, whereas the Swedish registry demon-
strated a much longer drug exposure, with a wide
range of variability among patients. Adalimumab,
among the most frequently used biologics, was ad-
ministered in similar percentages of patients among
all three databases (about 21% of patients). Systemic
steroids were used in similar percentages of patients
and with the same drug exposure in BiKeR and Phar-
machild, whereas the Swedish registry administered
shorter cycles of steroids in a smaller number of
Table 1 Demographic and clinical characteristics of the juvenile idiopathic arthritis patients from different registries
Pharmachild
N = 8274
BiKeR
N = 3990
Sweden
N = 3020
Number of countries 32 2# 1
Number of centers 86 72 33
Number of patients per center 55.5 (17–124) 10.5 (3–39.8) 52 (31–78)
Age at onset 5.4 (2.4–10.0) 7.6 (3.2–11.7) 7.6 (2.9–11.7)1
Age at JIA diagnosis 6.2 (2.8–10.9) – 8.3 (3.5–12.8)2
Disease duration at last visit 5.3 (2.7–8.8) 6.1 (3.5–9.5) 6.8 (4.3–10.1)3
Female 5584 (67.5%) 2670 (66.9%) 1989 (65.9%)
Antinuclear antibodies (ANA)* 1767 (21.4%) 1900 (47.6%) –
ILAR JIA category 4 5
Systemic 911 (11.0%) 267 (6.7%) 109 (4.7%)
Oligo 3071 (37.1%) 1215 (30.5%) 1148 (49.6%)
Oligo persistent 2011 (24.3%) 494 (12.4%) –
Oligo extended 1060 (12.8%) 721 (18.1%) –
Polyarticular RF− 2183 (26.4%) 1192 (29.9%) 568 (24.6%)
Polyarticular RF+ 322 (3.9%) 243 (6.1%) 85 (3.7%)
Psoriatic arthritis 285 (3.4%) 296 (7.4%) 160 (6.9%)
Enthesitis-related arthritis 924 (11.2%) 649 (16.3%) 185 (8.0%)
Undifferentiated arthritis 578 (7.0%) 127 (3.2%) 58 (2.5%)
Data are medians (1st–3rd quartiles) or frequencies (percentages)
*ANA at least two consecutively positive determinations according to local standards
# Germany and Austria
1data available for 2477 subjects
2data available for 2197 subjects
3data available for 2479 subjects
4data available for 3989 subjects
5data available for 2313 subjects
Abbreviations: BiKeR Biologics in Pediatric Rheumatology Registry, ILAR International League of Associations for Rheumatology, JIA juvenile idiopathic arthritis, RF
rheumatoid factor
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patients (about 40% of patients in Pharmachild and
BiKeR versus 16.7% in the Swedish registry).
Safety data
Overall, the German registry showed a higher incidence
of AEs but with lower intensity. In Pharmachild, 1599
(19.3%) of 8274 patients reported at least one moderate
AE compared with 1747 (43.8%) of 3999 AEs of any in-
tensity patients in BiKeR. Indeed, when the AEs of at
least moderate intensity were compared between the
two registries, the differences were less pronounced
(18.5% for Pharmachild versus 10.2% in BiKeR). Serious
AEs were present in 572 patients (6.9%) in Pharmachild
versus 297 (7.4%) in BiKeR. Among them, 13 deaths
were reported in Pharmachild and 3 in BiKeR mainly
due to severe infections or malignancies or both.
Table 3 reports a total of 5173 AEs in Pharmachild
and 5013 in BiKeR, according to the MedDRA diction-
ary divided by system organ class (SOC). Infection and
infestations resulted as the most frequent SOC in
Table 2 Number of patients who ever received a drug from onset to last available follow-up visit, with the corresponding days of
drug exposure per medication from the first day of drug administration to the last available follow-up visit
Pharmachild
N = 8274
Days of drug exposure
BiKeR
N = 3990
Days of drug exposure
Sweden
N = 3020
Days of drug exposure
DMARDs Methotrexate 6963 (84.2%);
924 (449–1747)
3344 (83.8%);
494 (173–957)
1842 (61%);
1198 (555–2127)
Sulfasalazine 861 (10.4%);
360 (143–730)
274 (6.9%);
174 (32–470)
95 (3%)
443 (132–1042)
Cyclosporine 518 (6.3%);
616 (235–1358)
113 (2.8%);
186 (62–580)
16 (0.5%);
584 (250–1452)
Leflunomide 372 (4.5%);
434 (182–888)
219 (5.5%);
267 (68–701)
2 (0.1%);
840 (511–1169)
Hydroxychloroquine 279 (3.4%);
486 (202–1022)
106 (2.7%);
182 (1–535)
32 (1.1%);
957 (311–1612)
Azathioprine 108 (1.3%);
439 (187–973)
155 (3.9%);
186 (26–494)
31 (1%);
1171 (340–2179)
Thalidomide 35 (0.4%);
290 (85–665)
0 0
Systemic glucocorticoids 3299 (39.9%)
206 (67–648)
1680 (42.1%)
196 (81–449)
503 (16.7%)
91 (35–437)
Biologics Etanercept 3600 (43.5%);
719 (300–1338)
2467 (61.8%);
489 (184–934)
726 (24%);
827 (341–1666)
Adalimumab 1778 (21.5%);
442 (174–927)
810 (20.3%);
350 (117–755)
657 (21.8%);
701 (292–1604)
Infliximab 705 (8.5%);
425 (160–951)
68 (1.7%);
213 (129–717)
189 (6.3%);
825 (328–1738)
Tocilizumab 633 (7.7%);
351 (126–742)
281 (7%);
377 (127–730)
122 (4%);
660 (193–1353)
Abatacept 420 (5.1%);
342 (156–715)
101 (2.5%);
190 (83–582)
80 (2.6%);
378 (164–1125
Anakinra 339 (4.1%);
299 (94–837)
50 (1.3%);
304 (9–806)
48 (1.6%);
422 (144–836)
Golimumab 161 (1.9%);
270 (106–623)
63 (1.6%);
344 (88–783)
93 (3.1%);
796 (370–1743)
Canakinumab 145 (1.8%);
351 (133–1032)
39 (1%);
364 (214–733)
7 (0.2%);
654 (604–1654)
Rituximab 103 (1.2%);
42 (24–87)
4 (0.1%);
15 (0–108)
20 (0.7%);
129 (15–1550)
Certolizumab 33 (0.4%);
166 (106–309)
4 (0.1%);
49 (0–110)
8 (0.3%);
984 (714–1538)
Other biologic agents 14 (0.2%);
217 (54–432)
4 (0.1%);
77 (25–149)
2 (0.1%);
325 (223–426)
Data are numbers of patients with frequencies (percentage), and medians and 1st–3rd quartiles of days of drug exposure
Abbreviations: BiKeR Biologics in Pediatric Rheumatology Registry, DMARD disease-modifying anti-rheumatic drug
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Pharmachild and BiKeR (29.4% versus 30.1%, respect-
ively) followed by gastrointestinal disorders (11.5% ver-
sus 19.6%) whereas all remaining SOCs occurred in less
than 10% of the AEs. In Pharmachild, more injuries, poi-
soning, and complications and hematological and hepa-
tobiliary disorders were reported compared with BiKeR,
which showed more investigations, general disorders
and administration site conditions, and neurological and
immune system disorders. The numbers of uveitis, in-
cluded in “Eye disorders” category, were comparable in
the two registries (5.2% versus 6.2% in Pharmachild and
BiKeR, respectively).
These results were confirmed by analyzing the distri-
bution of AEs separately for the retrospective and the
prospective visits. We identified a total of 1050 AEs ex-
tracted from the prospective visits, and 4123 events by
the retrospective data, divided by SOC. In general, the
hierarchy and frequency of AEs were similar, and infec-
tions and infestations were the most frequent events
(Additional file 2).
Table 4 reports details for the 2022 and 1697 common
ESIs in Pharmachild and BiKeR, respectively. The most
frequent ESIs were infections, which were the most
prevalent in both registries (75.3% versus 89% in Phar-
machild and BiKeR, respectively), followed by blood
cell–related ESIs. In Pharmachild, infusion/injection-re-
lated reactions were more frequent than in BiKeR
(10.8% versus 1.4%).
There were 27 cases of tuberculosis reported in Phar-
machild (52% from Asia, 37% from Europe, and 11%
from the US) and none in BiKeR, whereas all serious/
targeted infections were 674 (33.3%) and 171 (10.1%), re-
spectively; 17 cases of tuberculosis were during biologic
therapy, namely TNF inhibitors in 14 patients.
There were few cases of malignancies reported in ei-
ther registry. Besides the reported cases of hematological
malignancies in Table 4, in Pharmachild we could ob-
serve 10 additional cases (neoplasm others), represented
for one third by hemangioma, and with the remaining
patients suffering from thyroid cancer, cervix neoplasm,
skin tumors, breast fibroadenoma, colon adenoma, and
osteochondroma. The German registry reported in the
same group similar malignancies, in particular of the
genital apparatus (thyroid carcinoma, germ cell tumor,
anaplastic ependymoma, and cervix dysplasia).
Discussion
Since the 1990s, when the first immunomodulatory
products for rheumatic diseases were introduced, the
benefits of synthetic and biologic DMARDs became
clear in the management of JIA. Currently, however,
safety information for JIA is derived mainly from phase
III clinical trials and more recent registries and adminis-
trative claims. Therefore, little information exists on the
long-term safety of these agents. In 2009, a great scien-
tific debate regarding the safety of TNF blockers started,
prompting the FDA to issue a warning regarding a pos-
sible association between the use of TNF blockers and
the development of lymphoma and other cancers in chil-
dren and young adults with JIA [29]. Until now, owing
to confounding factors such as the use of concomitant
immunosuppressants, the effect of biological therapies
on the risk to develop cancer or other risks such as in-
fections in JIA is still controversial [30]. Literature has
provided evidence that an increased risk of malignancy
exists among children with JIA when compared with the
Table 3 Total number of adverse events by MedDRA system
organ class ordered by decreasing frequencies
Pharmachild
N = 5173
BiKeR
N = 5013
Infections and infestations 1523 (29.4%) 1509 (30.1%)
Gastrointestinal disorders 595 (11.5%) 984 (19.6%)
Injury, poisoning and procedural
complications
325 (6.3%) 152 (3.1%)
Blood and lymphatic system disorders 291 (5.6%) 99 (2%)
Investigations 285 (5.5%) 377 (7.5%)
Eye disorders 270 (5.2%) 309 (6.2%)
Skin and subcutaneous tissue disorders 256 (4.9%) 217 (4.3%)
General disorders and administration
site conditions
245 (4.7%) 410 (8.2%)
Hepatobiliary disorders 233 (4.5%) 24 (0.5%)
Surgical and medical procedures 209 (4.1%) 98 (2%)
Nervous system disorders 151 (2.9%) 227 (4.5%)
Musculoskeletal and connective tissue
disorders
147 (2.8%) 138 (2.7%)
Respiratory, thoracic, and mediastinal
disorders
112 (2.2%) 50 (1%)
Psychiatric disorders 105 (2.1%) 157 (3.1%)
Endocrine disorders 104 (2.0%) 6 (0.1%)
Metabolism and nutrition disorders 77 (1.5%) 34 (0.7%)
Renal and urinary disorders 66 (1.3%) 21 (0.4%)
Immune system disorders 33 (0.6%) 77 (1.5%)
Vascular disorders 30 (0.6%) 46 (0.9%)
Reproductive system and breast disorders 26 (0.5%) 13 (0.3%)
Congenital, familial, and genetic disorders 22 (0.4%) 9 (0.2%)
Cardiac disorders 19 (0.4%) 13 (0.3%)
Neoplasms benign, malignant, and
unspecified (including cysts and polyps)
16 (0.3%) 29 (0.6%)
Ear and labyrinth disorders 13 (0.3%) 7 (0.1%)
Social circumstances 11 (0.2%) 0
Pregnancy, puerperium and perinatal
conditions
9 (0.2%) 7 (0.1%)
Data are absolute numbers and frequencies (percentage)
Abbreviation: BiKeR Biologics in Pediatric Rheumatology Registry, MedDRA
Medical Dictionary for Regulatory Activities
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general population, irrespective of medication use. Con-
versely, other studies have not confirmed these findings,
highlighting the need of further studies to estimate this
risk more accurately [11, 13, 31, 32]. In order to address
this and other safety concerns more reliably, several
methods for pharmacovigilance could be implemented,
spanning from the results of phase II and III clinical
trials to post-marketing passive reporting or from regis-
tries (not-for-profit or sponsored by pharmaceutical
companies) [10, 33]. For this purpose, several registries
have been created in the last decade; in particular, the
national pediatric rheumatology societies in European
countries and in North America initiated independent
registries or registries in collaboration with pharmaceut-
ical companies for the long-term evaluation of the safety
and effectiveness mainly of biologic DMARDs [26, 28,
33–37]. Other research groups have concentrated their
efforts on the analysis of insurance claims [30, 38].
PRINTO implemented Pharmachild in order to guaran-
tee a critical mass of patients’ data and to provide sys-
tematically obtained evidence for provision of reliable
scientific data for health professionals and health author-
ities. Aiming to avoid overlapping of data collection and
to find an agreement on the proper way to share com-
mon data, a considerable number of European pediatric
rheumatology societies (for example, in France, the
Netherlands, Spain, and the Czech Republic primarily)
agreed to use Pharmachild as their primary resource for
data collection.
This article is the first attempt to present a very large
sample of data on JIA patients from different registries,
providing an overview on the baseline characteristics
from international and national registries. This analysis
highlights some differences but also similarities. An im-
portant difference that was observed was the higher fre-
quency of AEs in the German BiKeR registry, even
though associated with a lower intensity, which may re-
flect the different inclusion criteria of the two registries.
Indeed, in Pharmachild, events of mild intensity, defined
as transient or mild discomfort (<48 h) and no medical
intervention/therapy required, are excluded. This differ-
ence is the trade-off implemented in Pharmachild in
order to concentrate on more important safety events
and facilitate data collection in everyday busy clinical
practice.
Similarities among registries regarding therapies and
AEs could be identified. MTX was the most used syn-
thetic DMARD. ETN was the most frequently used bio-
logic agent in all registries considered, followed by
adalimumab. Drug exposure differed the three databases;
in BiKeR, it was lower for almost all the medications; in
the Swedish registry, it was much longer and had a
wider range of exposure variability despite the similar
disease duration. The relatively high rate of ETN use in
the BiKeR registry might be explained by the fact that
this registry originally started as a registry for this spe-
cific drug, when ETN was the only approved biological
drug in pediatric rheumatology and then extended to
other medications after their approval. However, in more
recent years in BiKeR, ETN is the first biologic in about
two thirds of patients with non-systemic JIA. Systemic
steroids were used much less in Sweden and for shorter
periods and this was maybe due to the lower incidence
Table 4 Total number of events of special interest ordered by
decreasing frequencies
Pharmachild
N = 2022
BiKeR
N = 1697
Infections: 1523 (75.3%) 1509 (89%)
Serious/targeted infections (Epstein–
Barr virus, cytomegalovirus, papilloma
virus, herpes zoster primary and
reactivation, and opportunistic
infections)
674 (33.3%) 171 (10.1%)
Tuberculosis 27 (1,3%) 0
Other infections 822 (40.6%) 1338 (78.8%)
Infusion/injection related reactions: 218 (10.8%) 24 (1.4%)
Infusion related reaction 144 (7.1%) 11 (0.6%)
Injection related reaction 74 (3.7%) 13 (0.8%)
Blood cell–related events of special
interest (ESI):
188 (9.3%) 90 (5.3%)
Pancytopenia 6 (0.3%) 65 (3.8%)
Neutropenia 107 (5.3%) 14 (0.8%)
Macrophage activation syndrome 75 (3.7%) 11 (0.6%)
Aplastic anemia 0 0
Autoimmune ESI: 50 (2.5%) 50 (2.9%)
Inflammatory bowel disease (IBD) 21 (1.1%) 23 (1.3)
Other autoimmune diseases excluding
IBD, uveitis, and demyelinisation disorders
18 (0.9%) 24 (1.4%)
Lupus erythematosus systemic/lupus-
like syndrome
4 (0.2%) 1 (0.1%)
Optic neuritis 4 (0.2%) 0
Multiple sclerosis 2 (0.1%) 0
Demyelination 1 (0.05%) 2 (0.2%)
Malignancies: 16 (0.8%) 13 (0.8%)
Leukemias 3 (0.1%) 2 (0.2%)
Lymphomas 2 (0.1%) 5 (0.3%)
Hematopoietic neoplasms (excluding
leukemias and lymphomas)
1 (0.05%) 2 (0.2%)
Neoplasm (other) 10 (0.5%) 4 (0.2%)
Others ESI: 27 (1.3%) 11 (0.6%)
Gastrointestinal (GI) ulcer/GI bleed/GI
perforation
17 (0.8%) 4 (0.2%)
Pregnancy 9 (0.4%) 7 (0.4%)
Congestive heart failure 1 (0.05%) 0
Data are absolute numbers and frequencies (percentage)
Swart et al. Arthritis Research & Therapy          (2018) 20:285 Page 8 of 11
of systemic JIA. In regard to ESIs, infections were the
most common event in both Pharmachild and BiKeR
registries whereas malignancies were reported in a lim-
ited number of patients. The overall frequencies of the
different AEs and ESIs were similar between Pharma-
child and BiKeR. The major differences when comparing
Pharmachild with BiKeR were higher frequencies of tu-
berculosis infection and infusion/injection-related reac-
tions in the first for a possible interviewer bias elicited
by the Pharmachild CRFs, which explicitly focus the at-
tention of the clinicians to these AEs. The difference in
the rate of tuberculosis infections may also reflect a dif-
ferent risk among European countries and the need for
higher awareness of this problem in some regions.
Next to reporting baseline data from a large sample of
patients with JIA , this study could not merge individual
patient data because of the lack of homogeneous infor-
mation. Therefore, it can be seen as a practical proposal
for future studies that involve data merging. We propose
a three-step procedure for future studies. In step 1, the
CRFs of the different registries should be compared
highlighting the similarities and differences. Step 2 will
verify the database technical characteristic (for example,
Sql server version 2005 and Access 2010) and the field
coding (for example, gender, int, 1 = male; 2 = female).
The third step related to the individual patient’s data
merging. An Excel spreadsheet with the data specifica-
tions related to a specific article will be shared with the
participating registries. Each registry will have to add its
own data related to the project. The coordinator of the
project will merge the individual patients’ data after
proper coding transformation. A census (for example,
few demographic data of all patients in the registry) will
be provided by each registry as a preliminary step to
check for a potential selection bias. The coordinator will
then prepare an additional spreadsheet to highlight the
important missing information (query log) to be resolved
in a timely manner in order to proceed with the final
analysis and drafting of the article. The entire procedure
may meet some obstacles due to the lack of homoge-
neous information among registries and ethical and data
protection regulations that often inhibit the exchange of
patient data. Nevertheless, the methodological approach
proposed to merge the data appears to be a successful
tool for increasing the number of patients and data for
future studies.
A possible limitation to our study is that a relevant
part of clinical information comes from retrospective
data with no efficacy results available. Nevertheless, as
pointed out in Additional file 2, retrospective data in
Pharmachild were mostly overlapping with prospective
data, thus supporting the validity of these safety findings.
This limitation becomes crucial when we consider effi-
cacy data, which can be provided only by the prospective
analysis. For this reason, further work in the future will
be focused on these patients in order to advance the use
of JIA drugs through the study of the Pharmachild popu-
lation. Future analytical work will also have to report ac-
cumulated patient years of treatment for each of the
registries.
Conclusions
This article is the first attempt to present a very large
sample of data on JIA patients from different national
and international registries and represents the first pro-
posal for sharing of data from national and international
registries as the most powerful tool for future analysis of
safety and effectiveness, with the aim to address import-
ant questions on current daily practice in pediatric
rheumatology.
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